echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Semin Arthritis Rheu: The prognosis of rheumatoid arthritis patients infected with the new crown

    Semin Arthritis Rheu: The prognosis of rheumatoid arthritis patients infected with the new crown

    • Last Update: 2021-09-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Since 2020, many patients with rheumatism have unfortunately been infected with the new coronavirus


    This is a comparative cohort study that uses the multicenter research network (TriNetX) in the United States to extract data on all adult RA patients and non-RA patients with COVID-19 from January 20, 2020 to April 11, 2021


    The study included 9730 RA patients with confirmed COVID-19 and 656,979 non-RA patients with COVID-19


    The mortality rate of the RA cohort, hospitalization rate, ICU occupancy rate, mechanical ventilation, severe COVID-19, acute kidney injury, renal replacement therapy/hemodialysis, acute respiratory distress syndrome-ARDS, ischemic stroke, venous thromboembolism-VTE, and sepsis risk are higher than those of non-RA Patients with new crowns are higher than non-RA patients with new crowns.



    Comparison of risk of outcome before and after matching between RA cohort and non-RA cohort

    This study found that before matching, the risk of all adverse outcomes in the RA cohort was higher than that in the non-RA cohort.


    The risk of VTE and sepsis in the RA cohort was consistently elevated, indicating that RA is an independent risk factor


    Original source:

    Rahul Raiker.




    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.